

RituxiMab in INDuction therapy for living donor renal transplantation

| | | |
|--|---|--|
| Submission date 01/10/2009 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 15/12/2009 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 27/01/2023 | Condition category Surgery | <input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Kidney transplantation is the best treatment for end stage kidney disease. Immunosuppression (reducing the strength of the body's immune system) prevents rejection and prolongs the life of a transplant. However, long-term graft loss remains a problem with an incidence of up to 20%. This is mainly due to immune system cells called B cells and the side effects of immunosuppression. Rituximab is a drug that targets B cells, reducing their numbers, and there is evidence that it reduces rejection. The aim of this study is to determine whether rituximab in combination with reduced immunosuppression can be used in kidney transplants to reduce the side effects of immunosuppression.

Who can participate?

Patients aged over 18 receiving their first living donor kidney transplant, or their second if the first was not lost from acute rejection

What does the study involve?

Participants are randomly allocated to either receive rituximab or to not receive rituximab 2 - 4 weeks before receiving their kidney transplant.

What are the possible benefits and risks of participating?

The potential benefits are significant. If rituximab is effective, patients could be safely managed with a reduced immunosuppressive treatment, which would lead to better graft function, lower rates of post-transplant diabetes, heart complications and infections, and potentially less rejection. This could result in improved long-term graft and patient survival: this would profoundly affect the approach to immunosuppression in kidney transplantation. There are two potential risks for participants: side effects due to rituximab administration, and the risks of rejection related to a reduced immunosuppressive treatment. These will be closely monitored during the study.

Where is the study run from?

Guy's Hospital, Derriford Hospital, Glasgow Renal and Transplant Unit, Queen Elizabeth Hospital Birmingham, Sheffield Kidney Institute and Manchester Renal Transplant Unit (UK).

When is the study starting and how long is it expected to run for?
November 2010 to November 2021

Who is funding the study?
Astellas Pharma and Guy's Hospital Transplant Surgical Research Fund (UK)

Who is the main contact?
Nizam Mamode
mamode@sky.com

Contact information

Type(s)
Scientific

Contact name
Mr Nizam Mamode

Contact details
Renal Unit, 6th Floor, Borough Wing
Guy's Hospital
1 St Thomas Street
London
United Kingdom
SE1 9RT
+44 (0)20 7188 8476
mamode@sky.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT01095172

Secondary identifying numbers
Study ID: 9154

Study information

Scientific Title
A phase IV open label randomised controlled trial of rituximab in induction therapy for living donor renal transplantation

Acronym
ReMIND

Study objectives

Can the use of a single dose of rituximab at induction allow a maintenance regimen of low dose tacrolimus and mycophenylate alone?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Guy's Research Ethics Committee, 25/01/2010, ref: 09/H0804/110

Study design

Phase IV open-label randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Live donor renal transplantation

Interventions

Pre-medication with paracetamol 1 g orally (PO), hydrocortisone 100 mg intravenously (IV) and chlorphenamine 10 mg IV is provided 30 minutes before start of rituximab infusion. A single dose of rituximab 375 mg/m² administered via a dedicated IV line is given 2 - 4 weeks prior to transplantation. The dose should be rounded to the nearest 100 mg unless the difference comprises more than 5% of calculated dose, in which case the dose should be rounded up to the nearest 10 mg.

Patients then receive the medications as below:

1. Basiliximab (Simulect®): 20 mg IV 1 hour prior to induction of anaesthesia, and a further 20 mg IV dose on day 4 post-transplant
2. Tacrolimus: dose calculated to give levels of 3 - 7 ng/ml
3. Mycophenylate mofetil: 2 g/day in divided doses
4. Prednisolone: all patients will be given 1 g methylprednisolone at induction of anaesthesia. Patients receiving rituximab will be given 100 mg hydrocortisone twice daily (bd) on day 1 after transplantation, then prednisolone at 0.3 mg/kg on day 2, 0.25 mg/kg on day 3, 0.2 mg/kg on day 4 and 0.16 mg/kg on day 5. On day 6 they will receive 5 mg prednisolone, and on day 7 none. For patients not receiving rituximab, our current protocol will be followed. Prednisolone will

continue at 0.3 mg/kg for the first month after transplantation, 0.25 mg/kg for months 2 and 3, and 0.16 mg/kg for months 4 to 6. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Rituximab, tacrolimus, mycophenylate

Primary outcome measure

Glomerular filtration rate (GFR) (Modification of Diet in Renal Disease [MDRD] study calculation) at 12 months

Secondary outcome measures

1. Biopsy proven acute rejection, graft and patient survival at 1 year
2. Infections
3. Post-transplant lymphoproliferative disorder (PTLD)

Overall study start date

16/11/2010

Completion date

16/11/2021

Eligibility**Key inclusion criteria**

1. Adult patients aged over 18 years, either sex
2. Receiving their first living donor renal transplant, or their second if the first was not lost from acute rejection
3. Have given written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

316

Key exclusion criteria

Amendments as of 22/12/2010:

Point 8 of the below exclusion criteria has been amended to read as follows:

8. Patients who have been involved in any other investigational trial or non protocol immunosuppressive regimen in the previous 90 days prior to transplant

Initial information at time of registration:

1. Previous other organ transplants lost through acute rejection
2. Patients undergoing antibody removal
3. Patients with other organ transplants
4. Patients previously treated with cylophosphamide, ATG, OKT3 or rituximab
5. Patients with white cell count below 4,500/mm³
6. Patients with platelet count below 1,500/mm³
7. Patients who are treated with drugs that are strong inhibitors or inducers of cytochrome P450, or treated with terfenadine, astemizole, cisapride or lovastatin
8. Patients who have been involved in any other investigational trial or non protocol immunosuppressive regimen in the previous 30 days prior to transplant
9. Pregnant or breastfeeding women
10. Patients with a documented history of malignancy and its origins and treatment in the last five years. Localised basal cell carcinoma of the skin is permitted
11. Patients known to be human immunodeficiency virus (HIV), hepatitis B or C surface antigen positive
12. Patients who in the opinion of the Investigator would not be a suitable candidate for study participation

Date of first enrolment

16/11/2010

Date of final enrolment

30/11/2018

Locations

Countries of recruitment

England

Scotland

United Kingdom

Study participating centre

Guy's Hospital

London

United Kingdom

SE1 9RT

Study participating centre

Derriford Hospital

Derriford Road
Plymouth
United Kingdom
PL6 8DH

Study participating centre**Glasgow Renal and Transplant Unit**

Greater Glasgow & Clyde NHS trust
Western Infirmary
Dumbarton Road
Glasgow
United Kingdom
G11 6NT

Study participating centre**Renal Transplant Unit**

Queen Elizabeth Hospital Birmingham
Mindelsohn Way
Edgbaston
Birmingham
United Kingdom
B15 2WB

Study participating centre**Sheffield Kidney Institute**

Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU

Study participating centre**Manchester Renal Transplant Unit**

Central Manchester University Hospitals
Manchester Royal Infirmary
Oxford Road
Manchester
United Kingdom
M13 9WL

Sponsor information

Organisation

Guy's and St Thomas' Hospital NHS Foundation Trust (UK)

Sponsor details

c/o Jackie Louise Pullen
Joint Clinical Trials Office
3rd Floor Conybeare House
Great Maze Pond
London
England
United Kingdom
SE1 9RT
+44 (0)20 7188 5732
jackie.pullen@kcl.ac.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.guysandstthomas.nhs.uk/>

ROR

<https://ror.org/00j161312>

Funder(s)

Funder type

Industry

Funder Name

Guy's Hospital Transplant Surgical Research Fund (UK)

Funder Name

Astellas Pharma Europe

Alternative Name(s)

Astellas Pharma Europe Ltd

Funding Body Type

Private sector organisation

Funding Body Subtype

International organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

It is intended that the results of the study will be reported and disseminated at international conferences and in peer-reviewed scientific journals.

Intention to publish date

16/11/2022

Individual participant data (IPD) sharing plan

-

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|--------------------------------------|---------|--------------|------------|----------------|-----------------|
| HRA research summary | | | 28/06/2023 | No | No |